AbolerIS Pharma Reveals Breakthrough Research on New Antibody for Autoimmune Treatments AbolerIS Pharma recently published new preclinical findings on ABO21009, a pioneering anti-CD45RC antibody that shows promise in treating autoimmune diseases.

AbolerIS Pharma Reveals Breakthrough Research on New Antibody for Autoimmune Treatments #Belgium #Autoimmune_Diseases #AbolerIS_Pharma #ABO21009 #Gosselies

AbolerIS Pharma Welcomes Philippe Alen as Chief Business Officer to Drive Growth in Biopharmaceuticals AbolerIS Pharma announces the appointment of Philippe Alen as Chief Business Officer to lead strategic initiatives and enhance partnerships in the biopharmaceutical field.

AbolerIS Pharma Welcomes Philippe Alen as Chief Business Officer to Drive Growth in Biopharmaceuticals #Belgium #Autoimmune_Diseases #AbolerIS_Pharma #Gosselies #Philippe_Alen

AbolerIS Pharma’s Breakthrough in Rheumatoid Arthritis Treatment with ABO21009 AbolerIS Pharma has initiated a Phase 1 study for ABO21009, a novel anti-CD45RC antibody aimed at treating rheumatoid arthritis, addressing unmet medical needs.

AbolerIS Pharma’s Breakthrough in Rheumatoid Arthritis Treatment with ABO21009 #Belgium #rheumatoid_arthritis #AbolerIS_Pharma #ABO21009 #Gosselies

AbolerIS Pharma Establishes Scientific Advisory Board for Advancing Treatment of Autoimmune Diseases AbolerIS Pharma has announced the formation of its Scientific Advisory Board to push forward its lead program ABO21009 for rheumatoid arthritis and beyond.

AbolerIS Pharma Establishes Scientific Advisory Board for Advancing Treatment of Autoimmune Diseases #Belgium #Autoimmune_Disease #AbolerIS_Pharma #ABO21009 #Gosselies